[HTML][HTML] Renal function assessment during peptide receptor radionuclide therapy
B Erbas, M Tuncel - Seminars in Nuclear Medicine, 2016 - Elsevier
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the
systemic treatment of various cancers including neuroendocrine tumors and prostate cancer …
systemic treatment of various cancers including neuroendocrine tumors and prostate cancer …
[HTML][HTML] Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
A Sabet, K Ezziddin, UF Pape, K Reichman… - European journal of …, 2014 - Springer
Purpose Renal radiation during peptide receptor radionuclide therapy (PRRT) may result in
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …
glomerular damage, a potential reduction of glomerular filtration rate (GFR) and ultimately …
[HTML][HTML] Significant impact of transient deterioration of renal function on dosimetry in PRRT
S Van Binnebeek, K Baete, C Terwinghe… - Annals of nuclear …, 2013 - Springer
Peptide receptor radionuclide therapy (PRRT), with 90 Y-DOTATOC and 177 Lu-DOTATATE
as most clinically used radiopeptides, is widely used in the management of metastatic …
as most clinically used radiopeptides, is widely used in the management of metastatic …
Renal dosimetry in peptide radionuclide receptor therapy
JA Siegel, MG Stabin, RM Sharkey - Cancer biotherapy & …, 2010 - liebertpub.com
This study evaluates the predictive value of absorbed dose, biological effective dose, and
time-dose-fractionation factors for use in patients receiving peptide radionuclide receptor …
time-dose-fractionation factors for use in patients receiving peptide radionuclide receptor …
[HTML][HTML] Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning—A …
B Nilica, A Svirydenka, J Fritz, S Bayerschmidt… - Revista Española de …, 2022 - Elsevier
Purpose Nephro-and hematotoxicity after peptide receptor radionuclide therapy (PRRT)
have been described in multiple studies with heterogeneous cumulative activities, number of …
have been described in multiple studies with heterogeneous cumulative activities, number of …
From Outside to Inside? Dose-Dependent Renal Tubular Damage After High-Dose Peptide Receptor Radionuclide Therapy in Rats Measured with In Vivo 99mTc …
F Forrer, E Rolleman, M Bijster, M Melis… - Cancer biotherapy & …, 2007 - liebertpub.com
In peptide receptor radionuclide therapy (PRRT), the dose-limiting organ is, most often, the
kidney. However, the precise mechanism as well as the exact localization of kidney damage …
kidney. However, the precise mechanism as well as the exact localization of kidney damage …
Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0, Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate
R Valkema, SA Pauwels, LK Kvols… - Journal of nuclear …, 2005 - Soc Nuclear Med
The kidneys are critical organs in peptide receptor radiation therapy (PRRT). Renal function
loss may become apparent many years after PRRT. We analyzed the time course of decline …
loss may become apparent many years after PRRT. We analyzed the time course of decline …
[PDF][PDF] Recent issues on dosimetry and radiobiology for peptide receptor radionuclide therapy
M Cremonesi, M Ferrari, A Di Dia, F Botta… - Quarterly Journal of …, 2011 - academia.edu
Peptide receptor radionuclide therapy (PRRT) has been constantly evolving over the last
decade, pro-viding successful results in the treatment of tumors expressing somatostatin …
decade, pro-viding successful results in the treatment of tumors expressing somatostatin …
Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management
A Chicheportiche, S Ben-Haim, S Grozinsky-Glasberg… - EJNMMI physics, 2020 - Springer
Background After each cycle of [177 Lu]-DOTA-TATE peptide receptor radionuclide therapy
(PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose …
(PRRT) dosimetry is performed to enable precise calculation of the radiation-absorbed dose …
[HTML][HTML] Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor …
S Van Binnebeek, K Baete, B Vanbilloen… - European journal of …, 2014 - Springer
Purpose Assessment of kidney function evolution after 90 Y-DOTATOC peptide receptor
radionuclide therapy (PRRT) with capped activity administration based on a 37-Gy threshold …
radionuclide therapy (PRRT) with capped activity administration based on a 37-Gy threshold …